LYCOS RETRIEVER 
Carisoprodol
built 644 days ago
Carisoprodol is metabolized in the liver via cytochrome P450 enzyme, CYP2C19. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 3-5%. Following a single 350 mg dose of Carisoprodol, the corresponding normalized peak concentration of meprobamate, which is a metabolite of Carisoprodol, was 2.08 ± 0.48 mcg/mL. These levels are approximately ¼ of those seen following a single 400 mg dose of meprobamate.
Source:
Carisoprodol is used as an adjunct to rest, physical therapy and other measures for relief of acute, painful musculoskeletal conditions. It is available in tablets containing either 350 mg carisoprodol or 200 mg carisoprodol in combination with 325 mg aspirin and 16 mg codeine phosphate. The standard dosage for adults is 350 mg three times daily and at bed-time. Use in patients under age 12 is not recommended. There were about 9.88 million prescriptions for carisoprodol prescribed in 2006 (IMS Health™).
Source:
Carisoprodol has fast, 30 minor attacks of operating, with the above mentioned property outcomes continuing for approximately of 2-6 hours. It metabolizes in a liver through cytochrome P450 an isoenzyme of oxydase CYP2C19, is secured discharged with nephroses and has a half-life approximate 8 hours. The considerable proportion carisoprodol metabolizes to 2--2--1,3--, which one is a known medicinal means of abuse and relation; it could explain a potential of abuse carisoprodol.
Source:
The pharmacokinetic profile of Carisoprodol in patients with renal impairment or hepatic impairment has not been evaluated. Because Carisoprodol is metabolized by the liver and excreted by the kidneys, possible increased exposure of Carisoprodol is expected if hepatic and/or renal function is impaired. The drug should be used with caution in patients with impaired hepatic or renal function.
Source:
NURSING MOTHERS: Carisoprodol accumulates in breast milk in concentrations twice those of the mother's blood. The effects of carisoprodol on the infants of lactating mothers are unknown. Therefore, caution is indicated when using carisoprodol in lactating women.
Source:
Carisoprodol is metabolized in the liver and is excreted by the kidneys. One of the products of metabolism, meprobamate, is active as an anxiolytic. The degree to which it contributes to the efficacy of Carisoprodol is unknown. Carisoprodol is dialyzable by peritoneal and hemodialysis.
Source:
MORE ABOUT
Carisoprodol